Article metrics

  • citations in SCindeks: 0
  • citations in CrossRef:0
  • citations in Google Scholar:[=>]
  • visits in previous 30 days:0
  • full-text downloads in 30 days:0
article: 2 from 12  
Back back to result list
Acta medica Medianae
2011, vol. 50, iss. 1, pp. 32-37
article language: Serbian
document type: Original Paper
published on: 28/06/2011
Disorders of phospho-calcemic balance in patients on chronic hemodialysis: Time-based duration relationship
Clinical Centre Niš, Clinic of Nephrology



Chronic renal failure (CRF) is a progressive, irreversible deterioration of kidney function that leads to complete loss of kidney function and the need for dialysis treatment. Bone disease is a chronic complication in the CRF and poses a significant problem in hemodialysis patients. The aim of our study was to assess the influence of peritoneal dialysis treatment on biochemical parameters of mineral and bone metabolism in hemodialysis patients, and identify the most important parameters for the monitoring of this disorder. The research involved 172 patients, mean age 58.69±12:54, divided into groups in respect to the length of dialysis treatment (group I - 5 years, group II - 5-10 years and group III - over 10 years). Serum phosphorus in all the patients was increased, but the values increased with duration of dialysis (I: 1.77±0.58, II: 1.97±0.66, III: 1.92±0.82), with no statistical differences (p>0.05). Calcemia values were significantly increased (I vs. II. and I vs. III, p<0.0001), as well as the values of Ca x P (I vs. II., p<0.001, II vs. III., p<0.01), primarily on the account of the increased calcium value. The values of alkaline phosphatase (I: 105.12±65.60; II: 125.27±96.79, III: 172.43±163.99) were significantly higher in group III compared to other groups (p <0.05). Also, the values of PTH (I: 234.21±18.74; II: 273.09±247.98; III: 489.46±468.49) were significantly higher in group III compared to other groups (p<0.001). In the group of patients with duration of dialysis up to 5 years, the values of phosphorus were increased, the values of calcemia were decreased, with mild elevation of AF and PTH values, which best corresponds to the bone disease with rapid turnover. In the P group, there is a significant increase in calcemia in respect to phosphorus, alkaline phosphatase, and PTH. The most reliable marker for clinical monitoring of bone disease in dialysis patients is PTH, which correlates well with the values of alkaline phosphatase and calcium. The values of calcium and phosphorus are highly variable and not the most reliable markers for bone disease monitoring.



*** (2004) SPSS: Data analysis with comprehensive statistics software 'computer program': Version 16:0. SPSS Inc
Arenas, D.M., Alvarez-Ude, F., Gil, T.M., Soriano, A., Egea, J.J., Millán, I., Amoedo, L.M., Muray, S., Carretón, A.M. (2006) Application of NKF-K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease: Changes of clinical practices and their effects on outcomes and quality standards in three haemodialysis units. Nephrology, dialysis, transplantation, 21(6): 1663-8
Brandi, L. (2008) 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol: An active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Danish medical bulletin, 55(4): 186-210
Cavalier, E., Delanaye, P., Collette, J., Krzesinski, J.M., Chapelle, J.P. (2006) Evaluation of different bone markers in hemodialyzed patients. Clin Chim Acta, 371(1-2):107-11
Fauci, A.S., Braunwald, E., Kasper, D.L., Hauser, S.L., Longo, D.L., Jameson, J.L., Loscalzo, J. (2008) Harrison's Principles of internal medicine. The McGraw-Hill Companies, Inc
Gal-Moscovici, A., Popovtzer, M.M. (2005) New worldwide trends in presentation of renal osteodystrophy and its relationship to parathyroid hormone levels. Clinical nephrology, 63(4): 284-9
Goodman, W.G. (2003) Medical management of secondary hyperparathyroidism in chronic renal failure. Nephrol Dial Transplant, 18 Suppl 3: iii2-8
Haese, D.P.C., Spasovski, G.B., Sikole, A., Hutchison, A., Freemont, T.J., Sulkova, S., Swanepoel, C., Pejanović, S., Đukanović, L., Balducci, A., Coen, G., Sulowicz, W., Ferreira, A., Torres, A., Curic, S., Popović, M., Dimković, N., de Broe, M.E. (2003) A multicenter study on the effects of lanthanum carbonate (Fosrenol (TM)) and calcium carbonate on renal bone disease in dialysis patients. Kidney International, 63: S73-S78
Ilić, S. (2004) Interna medicina. Niš: Medicinski fakultet
Jesri, A., Braitman, L.E., Pressman, G.S. (2008) Severe mitral annular calcification predicts chronic kidney disease. International journal of cardiology, 128(2): 193-6
Jonić, N., Đorđević, V., Đorđević, N., Ljubenović, S. (2008) Uticaj dužine trajanja hemodijalize, starosti i pola na pojavu simptoma renalne osteodistrofije. Acta medica Medianae, vol. 47, br. 4, str. 19-24
Jorge, C., Gil, C., Possante, M., Silva, E., Andrade, R., Santos, N., Cruz, A., i dr. (2005) Bone alkaline phosphatase besides intact parathyroid hormone in hemodialysis patients: Any advantage?. Nephron - Clinical Practice, 101 (3), str. C122-C127
Kostić, S.M., Paunović, G.J., Avramović, M.Ž., Veličković-Radovanović, R., Kostić, I., Stojanović, M. (2004) Hronična bubrežna insuficijencija danas. Acta medica Medianae, vol. 43, br. 3, str. 45-49
Locatelli, F., D'Amico, M., Cernevskis, H., Dainys, B., Miglinas, M., Luman, M., Ots, M., Ritz, E. (2001) The epidemiology of end-stage renal disease in the Baltic countries: An evolving picture. Nephrol Dial Transplant, 16(7): 1338-42
Moe, S., Drüeke, T., Cunningham, J., Goodman, W., Martin, K., Olgaard, K., Ott, S., Sprague, S., Lameire, N., Eknoyan, G. (2006) Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney international, 69(11): 1945-53
National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis, 39(2 Suppl 1): S1-266
Spasovski, G. (2007) New aspects of treatment of renal bone disease in dialysis patients. Contributions, Sec Biol Med Sci, 28(1):205-13
Spasovski, G.B., Bervoets, A.R.J., Behets, G.J.S., Ivanovski, N., Sikole, A., Dams, G., Couttenye, M.M., de Broe, M.E., Haese, P.D.C. (2003) Spectrum of renal bone disease in end-stage renal failure patients not yet on dialysis. Nephrology, dialysis, transplantation, 18(6): 1159-66
Tsukamoto, Y. (2007) Disorders of bone and mineral metabolism in CKD: CKD-MBD as a new entity. Clinical calcium, 17(5): 660-4